- Home
- ENTA vs ZJYL Comparison
ENTA vs ZJYL Comparison
Compare ENTA & ZJYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- ZJYL
- Stock Information
- Founded
- ENTA 1995
- ZJYL 2006
- Country
- ENTA United States
- ZJYL China
- Employees
- ENTA N/A
- ZJYL N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- ZJYL Industrial Specialties
- Sector
- ENTA Health Care
- ZJYL Consumer Discretionary
- Exchange
- ENTA Nasdaq
- ZJYL Nasdaq
- Market Cap
- ENTA 154.0M
- ZJYL N/A
- IPO Year
- ENTA 2013
- ZJYL 2023
- Fundamental
- Price
- ENTA $5.55
- ZJYL $0.90
- Analyst Decision
- ENTA Buy
- ZJYL
- Analyst Count
- ENTA 4
- ZJYL 0
- Target Price
- ENTA $17.25
- ZJYL N/A
- AVG Volume (30 Days)
- ENTA 178.5K
- ZJYL 234.3K
- Earning Date
- ENTA 05-12-2025
- ZJYL 05-20-2025
- Dividend Yield
- ENTA N/A
- ZJYL N/A
- EPS Growth
- ENTA N/A
- ZJYL 18.46
- EPS
- ENTA N/A
- ZJYL 0.02
- Revenue
- ENTA $66,590,999.00
- ZJYL $23,502,010.00
- Revenue This Year
- ENTA N/A
- ZJYL N/A
- Revenue Next Year
- ENTA N/A
- ZJYL N/A
- P/E Ratio
- ENTA N/A
- ZJYL $35.33
- Revenue Growth
- ENTA N/A
- ZJYL 18.57
- 52 Week Low
- ENTA $4.09
- ZJYL $0.56
- 52 Week High
- ENTA $17.24
- ZJYL $4.38
- Technical
- Relative Strength Index (RSI)
- ENTA 51.08
- ZJYL 57.20
- Support Level
- ENTA $4.96
- ZJYL $0.78
- Resistance Level
- ENTA $6.23
- ZJYL $0.85
- Average True Range (ATR)
- ENTA 0.34
- ZJYL 0.07
- MACD
- ENTA 0.01
- ZJYL -0.00
- Stochastic Oscillator
- ENTA 46.46
- ZJYL 71.37
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.